<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="368419">
  <stage>Registered</stage>
  <submitdate>22/04/2015</submitdate>
  <approvaldate>19/05/2015</approvaldate>
  <actrnumber>ACTRN12615000493549</actrnumber>
  <trial_identification>
    <studytitle>Cure rate and side effects comparison between the sequential bismuth based quadruple therapy and the concomitant bismuth based quadruple therapy in treating patients carrying antibiotic resistant Helicobacter pylori strain.</studytitle>
    <scientifictitle>Efficacy of sequential bismuth based quadruple therapy versus concomitant bismuth based quadruple therapy in treating patients carrying antibiotic resistant Helicobacter pylori strain.</scientifictitle>
    <utrn>U1111-1169-5022</utrn>
    <trialacronym />
    <secondaryid>Nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Helicobacter pylori unable to be eradicated with standard triple therapies.</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>sequential treatment (5 days of rabeprazole 20 mg three times a day and bismuth subcitrate (BIS) 240mg four times a day, followed by 5 days of rabeprazole 20 mg three times a day, BIS 240mg four times a day, rifabutin (RFB) 150 mg twice a day and ciprofloxacin (CIP) 500 mg twice a day.); All drugs are to be taken orally; Patients compliance was checked via phone interview. 

</interventions>
    <comparator>concomitant treatment (10 days of rabeprazole 20 mg three times a day, BIS 240mg four times a day, RFB 150 mg twice a day and CIP 500 mg twice a day).</comparator>
    <control>Dose comparison</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Treatment success, assessed by percentage of cured patients.</outcome>
      <timepoint>Because the followup diagnosis of these patients can vary from a month to several months and the rarity of reinfection of this organism, we would accept all patient's follow up diagnostic results up to two years.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>side effects comparison between the test group (sequential quadruple therapy) and the control group (concomitant quadruple therapy).

side effects data are collected based on a 5 min survey designed specifically for this study.

Most common side effects include, nausea, diarrhea, stomach pain, headache and dry mouth.</outcome>
      <timepoint>survey is given immediately after completion of treatment. </timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients must fail more than one standard triple therapy, which indicate carrying antibiotic resistant H. pylori strain. 
If antibiotic sensitivity testing was performed, the strain must be sensitive to Ciprofloxacin and Rifabutin.

</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>free of H. pylori infection, mental disability, pregnancy or lactation in women, known allergy or hypersensitivity to drugs used in study therapy, or current participation with other clinical trials.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>allocation not concealed</concealment>
    <sequence>coin-tossing</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods>Chi-square analysis to compare cure rate between two treatment groups.

student T-test to compare the overall side effects between two treatment groups.

We planned to use 2x2 contingency Chi square tests to compare the cure rates for the two regimens, and set the significance level at 0.05. From previous published work we knew the expected cure rate for concurrent PBRC treatment regimen (94%). We undertook power analysis to determine the number of participants needed to achieve a high power (&gt; 0.90) to pick-up a 75 % cure rate with the new regimen (sequential PBRC), with a cure rate held at 94% for the concurrent regimen. This outcome represents an effect size of just over 0.25 (for an effect size of 0.25, the sample size is 203). Hence, we ascertained that  the sample size should be approximately 200.
</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/01/2012</anticipatedstartdate>
    <actualstartdate>18/01/2012</actualstartdate>
    <anticipatedenddate>31/12/2013</anticipatedenddate>
    <actualenddate>10/12/2013</actualenddate>
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
    <hospital>Sir Charles Gairdner Hospital - Nedlands</hospital>
    <postcode>6009 - Nedlands</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Western Australia</primarysponsorname>
    <primarysponsoraddress>35, Stirling Highway, Crawley 6009, WA</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Western Australian Government’s Department of Commerce </fundingname>
      <fundingaddress>Level 5, The WestCentre, 1260 Hay Street, West Perth, WA 6005</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Western Australian Government’s Department of Health</fundingname>
      <fundingaddress>189 Royal Street 
East Perth WA 6004 
Australia</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council
grant number 572723</fundingname>
      <fundingaddress>GPO Box 1421
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>University of Western Australia’s Special Infrastructure Fund</fundingname>
      <fundingaddress>35, Stirling Highway, Crawley 6009, WA</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>none</sponsorname>
      <sponsoraddress>none</sponsoraddress>
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary aim of this study is to determine Efficacy of sequential bismuth based quadruple therapy versus concomitant bismuth based quadruple therapy in treating patients carrying antibiotic resistant Helicobacter pylori strain.</summary>
    <trialwebsite />
    <publication>Tay CY, Windsor HM, Thirriot F, Lu W, Conway C, Perkins TT, et al. Helicobacter pylori eradication in Western Australia using novel quadruple therapy combinations. Alimentary pharmacology &amp; therapeutics. 2012; 36(11-12): 1076-83.</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes>As mentioned in the Participant information sheet (PCIF), Page 2, this is an extension study from previous approved study, HREC 1999-026. Please find the closure of previous study in attachment.</publicnotes>
    <ethicscommitee>
      <ethicname>Sir Charles Gairdner and Osborne Park Health Care Group (SCGOPHCG)</ethicname>
      <ethicaddress>Level 2 A Block, Hospital Ave, Nedlands, WA 6009</ethicaddress>
      <ethicapprovaldate>10/10/2013</ethicapprovaldate>
      <hrec>2013-007</hrec>
      <ethicsubmitdate>5/02/2013</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Sir Charles Gairdner and Osborne Park Health Care Group (SCGOPHCG)</ethicname>
      <ethicaddress>Level 2 A Block, Hospital Ave, Nedlands, WA 6009</ethicaddress>
      <ethicapprovaldate>1/04/1999</ethicapprovaldate>
      <hrec>1999-026</hrec>
      <ethicsubmitdate>1/04/1999</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment>
    <filepath>http://www.anzctr.org.au/AnzctrAttachments/368419-Ethics approval 2013-007.pdf</filepath>
    <filepath>http://www.anzctr.org.au/AnzctrAttachments/368419-Study protocol 040713.pdf</filepath>
    <filepath>http://www.anzctr.org.au/AnzctrAttachments/368419-letter of invitation 050713.pdf</filepath>
    <filepath>http://www.anzctr.org.au/AnzctrAttachments/368419-PCIF 170913 - Copy.docx</filepath>
    <filepath>http://www.anzctr.org.au/AnzctrAttachments/368419-Treatment side effect form 200613.pdf</filepath>
    <filepath>http://www.anzctr.org.au/AnzctrAttachments/368419-Closure of 99-026 project.pdf</filepath>
  </attachment>
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Alfred Chin Yen Tay</name>
      <address>University of Western Australia
M504, 35 Stirling Highway, Crawley, WA 6009, </address>
      <phone>+61 8 93464817</phone>
      <fax />
      <email>alfred.tay@uwa.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Alfred Chin Yen Tay</name>
      <address>University of Western Australia
M504, 35 Stirling Highway, Crawley, WA 6009, </address>
      <phone>+61 8 93464817</phone>
      <fax />
      <email>alfred.tay@uwa.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Alfred Chin Yen Tay</name>
      <address>University of Western Australia
M504, 35 Stirling Highway, Crawley, WA 6009, </address>
      <phone>+61 8 93464817</phone>
      <fax />
      <email>alfred.tay@uwa.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Alfred Chin Yen Tay</name>
      <address>University of Western Australia
M504, 35 Stirling Highway, Crawley, WA 6009, </address>
      <phone>+61 8 93464817</phone>
      <fax />
      <email>alfred.tay@uwa.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>